Newscasting from EULAR 2024: Analysis Demonstrates Long-Term Safety Profile of Filgotinib for RA Treatment
The safety profile of filgotinib remained stable more than 4 years among a cohort of patients with moderate to severe rheumatoid arthritis (RA), according to an updated integrated safety analysis presented at the 2024 European Congress of Rheumatology (EULAR). These results were comparable to a previous analysis and no new safety information regarding adverse events of special interest (AESIs) were reported.
“The oral Janus kinase (JAK) 1-preferential inhibitor filgotinib is approved at doses of 100 mg (FIL100) and 200 mg (FIL200) for the treatment of moderate to severe active RA,” wrote a team of investigators led by Kevin Winthrop, MD, MPH, professor of Public Health at the Oregon Health and Science University, School of Medicine. “Previous integrated safety analyses from clinical trials have shown that safety and tolerability is broadly similar between the FIL doses, with a lower incidence of herpes zoster with FIL100 vs FIL200.”
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
